|Market Size in 2022||Market Forecast in 2030||CAGR (in %)||Base Year|
|USD 243.61 million||USD 379.51 million||5.70%||2022|
Chinese Hamster Ovary Cells (CHO) Market
The global chinese hamster ovary cells (CHO) market size was worth around USD 243.61 million in 2022 and is predicted to grow to around USD 379.51 million by 2030 with a compound annual growth rate (CAGR) of roughly 5.70% between 2023 and 2030.
The report delves deeper into several crucial aspects of the global Chinese hamster ovary cells (CHO) market. It includes a detailed discussion of existing growth factors and restraints. Future growth opportunities and challenges that impact the Chinese hamster ovary cells (CHO) industry are comprehensively addressed in the report.
Chinese hamster ovary cells (CHO) are scientifically known as Cricetulus griseus and are cells derived from the ovaries of Chinese hamsters. They are used extensively in the pharmaceutical and biotechnology industries for the production of recombinant proteins and therapeutic proteins. CHO cells have been preferred for several research purposes since they have shown exceptional results in terms of growing well in culture. They also tend to produce large amounts of recombinant proteins and are known for relatively simpler growth requirements. Moreover, their stable genetic characteristics further add to the reasons working in the favor of demand and application of CHO cells. They are commonly used for the production of monoclonal antibodies, hormones, growth factors, enzymes, and other biopharmaceuticals. The CHO cell industry is likely to register steady growth in the coming years.
Growing investment driving biopharmaceutical industry expansion to propel market growth
The global Chinese hamster ovary cells (CHO) market is projected to be driven by the increasing investment toward the expansion of the biopharmaceutical industry. In the last decade, the industry has become exceptionally important to the global healthcare and pharmaceutical sectors. Biopharmaceuticals have managed to provide answers to critical diseases which could not be cured using traditional medicines or therapies. The various components in the industry including biologic drugs, monoclonal antibodies, recombinant proteins, and gene therapies allow healthcare professionals to provide targeted therapies that are known to have a better success rate. Moreover, these therapies are being used to cure conditions such as cancer, autoimmune diseases, genetic disorders, and more. As the modern healthcare structure undertakes more research around biopharmaceuticals, the demand for CHO cells is likely to continue growing.
High cost of CHO cell-based production to restrict market expansion
Generally, the cost of CHO cell-based production processes tends to be higher than alternative expression systems such as microbial systems. CHO cells demand specialized growth media along with the use of an extremely complex purification process and extensive culture optimization. These factors are known to contribute to the overall cost of production which could limit the adoption of CHO cells for companies or research institutes working on a budget.
Rising efforts toward higher production of biosimilars to provide growth opportunities
The Chinese hamster ovary cells industry is expected to come across several growth opportunities led by the growing interest and efforts of the medical community toward increasing the production of biosimilars. They are known to be cost-effective alternatives to reference biologics and a large section of biosimilars make use of CHO cells. With the increasing demand for quality medical care and the highest expense associated with it, governments and healthcare agencies are looking at measures to contain surging healthcare costs which could trigger more demand for biosimilars and in turn impact the consumption level of CHO cells.
Scaling up of CHO cell-based biopharmaceutical products to challenge market expansion
The CHO cell industry growth is expected to be challenged by the problems surrounding scaling up the production of CHO cell-based biopharmaceuticals. While working with larger scales of CHO cells, it may be difficult to achieve consistent and reproducible yields due to the requirement of process optimization, including optimizing culture conditions, media formulations, and bioreactor design. This may be a barrier for the companies operating in the CHO cells industry to ensure scalability while maintaining product quality and minimizing the cost of production.
The global Chinese hamster ovary cells (CHO) market is segmented based on application, product, end-user, system, and region.
Based on application, the global market segments are clotting factors, monoclonal antibodies, hormones, cytokines, Fc-fusion protein, enzymes, and others. The industry registered the highest growth in the monoclonal antibodies (mAbs) segment in 2022 as CHO cells are used extensively for the production of mAbs. They are a class of biologic drugs that are used for the treatment of various diseases including infectious conditions, cancer, and autoimmune issues. Several beneficial attributes of CHO cells are the driving factors for a higher adoption rate. For instance, their ability to produce complex proteins with appropriate post-translational modifications, correct folding, and high yields. They offer advantages in terms of scalability, productivity, and regulatory acceptance. As of 2023, the global biopharmaceutical market is over USD 400 billion.
Based on product, the Chinese hamster ovary cells industry is segmented into CHO-DG44, CHO-K1, CHO-S, CHO-DXB1, and others.
Based on end-user, the global market divisions are contract development & manufacturing organization, biopharmaceutical companies, academic institute & research, biotech companies, clinical research organization, and others. The leading end-user of CHO cells in 2022 were known to be biopharmaceutical companies including larger corporations and small companies. They make use of CHO cells for the production of biologic drugs such as monoclonal antibodies, recombinant proteins, and other complex therapeutic molecules. In the industry, CHO cells have proven to offer a reliable and well-established platform for large-scale production of biopharmaceuticals. The academic institute & research centers may use CHO cells for studying protein expression, cell line engineering, process optimization, and other aspects of biopharmaceutical production. Between 2019 and 2022, the health research & development expenditure by the US federal government grew by USD 9.8 billion.
Based on the system, the global Chinese hamster ovary cells market is segmented into metabolic selection system and antibiotic selection system.
|Report Attributes||Report Details|
|Report Name||Chinese Hamster Ovary Cells (CHO) Market Research Report|
|Market Size in 2022||USD 243.61 Million|
|Market Forecast in 2030||USD 379.51 Million|
|Growth Rate||CAGR of 5.70%|
|Number of Pages||204|
|Key Companies Covered||Lonza Group Ltd., Thermo Fisher Scientific Inc., Merck KGaA, Sartorius AG, Catalent Inc., WuXi Biologics, GE Healthcare Life Sciences, Samsung Biologics, Boehringer Ingelheim BioXcellenc, MilliporeSigma, Fujifilm Diosynth Biotechnologies, GenScript Biotech Corporation, AGC Biologics, Selexis SA, Rentschler Biopharma SE, Celonic AG, Abzena Ltd., ProBioGen AG, BioVectra Inc., Eurofins BioPharma Product Testing, Glycotope GmbH, Horizon Discovery Group plc, Invetech, Lonza Biologics, and Fujifilm Irvine Scientific.|
|Segments Covered||By Application, By Product, By End-User, By System, and By Region|
|Regions Covered||North America, Europe, Asia Pacific (APAC), Latin America, Middle East, and Africa (MEA)|
|Historical Year||2017 to 2021|
|Forecast Year||2023 - 2030|
|Customization Scope||Avail customized purchase options to meet your exact research needs. Request For Customization|
North America to generate the highest revenue in the near future
The global Chinese hamster ovary cells (CHO) market is expected to register the highest growth in North America and particularly the United States. The steady growth trajectory is associated with the presence of a robust pharmaceutical and healthcare infrastructure in the US along with the presence of some of the biggest and most well-funded pharmaceutical companies that are constantly investing in revolutionizing the global biopharma segment. In addition to this, the US government has increased its total healthcare R&D expenditure along with an increased rate of investment toward regional healthcare infrastructure. The National Institute of Health spends the majority of its annual budget which currently stands at USD 45 billion on medical research. Additionally, the growing demand for targeted medical therapies and medications could lead to higher adoption of CHO cells for further research and medicine development.
The global Chinese hamster ovary cells (CHO) market is led by players like:
Chinese hamster ovary cells (CHO) are scientifically known as Cricetulus griseus and are cells derived from the ovaries of Chinese hamsters.
The global Chinese hamster ovary cells (CHO) market is projected to be driven by the increasing investment toward the expansion of the biopharmaceutical industry.
According to study, the global Chinese hamster ovary cells (CHO) market size was worth around USD 243.61 million in 2022 and is predicted to grow to around USD 379.51 million by 2030.
The CAGR value of the Chinese hamster ovary cells (CHO) market is expected to be around 5.70% during 2023-2030.
The global Chinese hamster ovary cells (CHO) market is expected to register the highest growth in North America and particularly the United States.
The global Chinese hamster ovary cells (CHO) market is led by players like Lonza Group Ltd., Thermo Fisher Scientific Inc., Merck KGaA, Sartorius AG, Catalent, Inc., WuXi Biologics, GE Healthcare Life Sciences, Samsung Biologics, Boehringer Ingelheim BioXcellenc, MilliporeSigma, Fujifilm Diosynth Biotechnologies, GenScript Biotech Corporation, AGC Biologics, Selexis SA, Rentschler Biopharma SE, Celonic AG, Abzena Ltd., ProBioGen AG, BioVectra Inc., Eurofins BioPharma Product Testing, Glycotope GmbH, Horizon Discovery Group plc, Invetech, Lonza Biologics, and Fujifilm Irvine Scientific.